The most common neurological deficits in children after surgery for congenital heart disease are fine and gross motor deficits. Recent magnetic resonance imaging studies have demonstrated a significant number of newly developed white matter (WM) lesions in infants after surgery. The present study describes region-specific WM development in the juvenile porcine brain, which is similar in developmental stage to the human newborn. Acute and long-term cellular responses to cardiopulmonary bypass in oligodendrocyte lineages and neuron-axonal elements, which are the most prominent cell populations in WM, have been observed. A uniquely susceptible cellular target of cardiopulmonary bypass-induced WM injury in the oligodendrocyte lineage, as well as maturation-dependent vulnerability of developing WM, was found. Oligodendrocyte progenitor cells, which mediate WM recovery function, are highly resistant to cardiopulmonary bypass-induced injury. Interestingly, oligodendrocyte progenitor cell number decreases with age, which suggests that immature WM is vulnerable but also retains a significant endogenous cellular potential for recovery. Therefore, the optimal time window for congenital heart disease repair is the period during which WM contains the largest number of oligodendrocyte progenitor cells. Importantly, it was identified that under conditions of higher cerebral oxygenation and lower inflammation, the maturation stage was not a crucial determinant of cardiopulmonary bypass-induced WM injury. Together with the recent clinical finding that newborns with congenital heart disease have delayed brain development due to abnormal cerebral circulation in utero, the present study suggests that earlier normalization of cerebral circulation by primary congenital heart disease repair using higher cerebral oxygenation and lower inflammation should improve WM development in this population. See p 859.
9-Cis Retinoic Acid Promotes Lymphangiogenesis and Enhances Lymphatic Vessel Regeneration: Therapeutic Implications of 9-Cis Retinoic Acid for Secondary Lymphedema
Lymphedema, or tissue swelling, is caused by abnormal tissue fluid accumulation resulting from lymphatic malformation or secondary lymphatic disruption resulting from lymph node dissection, irradiation, or parasite infection. Lymphedema is a disfiguring and painful illness and often is associated with tissue fibrosis and recurrent infection, thus significantly compromising patients' quality of life. Although hundreds of millions of people worldwide suffer from lymphedema in their lower extremities as a result of parasite infection, cancer survivors are the most common lymphedema patients in the United States because lymph node dissection and radiation therapies essentially obstruct the lymphatic function. Although the sentinel lymph node biopsy reduces the prevalence of lymphedema, the number of lymphedema patient is increasing as the cancer survival rate increases. However, effective treatments against lymphedema are not available beyond physical therapies. Therefore, our finding of the therapeutic efficacy of retinoic acids for experimental lymphedema presents an important breakthrough in the treatment of this disfiguring disease. Retinoic acids especially have been characterized extensively for their medicinal properties and thus can be implemented immediately in clinics. Our in vitro and animal studies demonstrate the prolymphangiogenic efficacy of retinoic acids and suggest that retinoic acids could be developed as an effective therapeutic agent to cure secondary lymphedema. See p 872.
Human Embryonic and Induced Pluripotent Stem Cell-Derived Cardiomyocytes Exhibit Beat Rate Variability and Power-Law Behavior
Atrioventricular conduction block and arrhythmias caused by sinoatrial node dysfunction are generally treated with electronic pacemakers. Although an excellent therapy, electronic pacemakers incorporate limitations that have stimulated research on biological pacing. Initial proof of concept has been followed by attempts to optimize biological pacemakers so that their function of generating stable basal rates and brisk autonomic responses is manifested over long intervals. Importantly, the functional features of the prototypical biological pacemaker, the sinoatrial node, are not limited to automaticity. Rather, the normal node has an organized rhythm that is stable over time, imposes a dominant rhythm on the cardiac substrate, and has autonomic responsiveness. Hence, it is likely desirable that at least a subset of fabricated biological pacemakers would function much like the sinoatrial node. To achieve this, we need additional understanding of the intrinsic firing patterns of cell types proposed for use as biological pacemakers with the sinoatrial node as an operational standard. To this end, we recorded extracellular electrograms from human embryonic and induced pluripotent stem cellderived cardiomyocytes, and the beat rate time series of the spontaneous activity were examined in terms of power spectral density and additional methods derived from nonlinear dynamics. In brief, we demonstrated that human embryonic and induced pluripotent stem cell-derived cardiomyocytes exhibit beat rate variability and powerlaw behavior as in humans, thus supporting the potential capability of these cell sources to serve as biological pacemakers. See p 883.
Gene Inactivation of Proprotein Convertase Subtilisin/ Kexin Type 9 Reduces Atherosclerosis in Mice
The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the low-density lipoprotein receptor and hence is a promising target to treat hypercholesterolemia and to prevent cardiovascular diseases. Clinical trials are currently under way to determine whether inhibiting PCSK9 is a safe and efficient approach in humans. The present study demonstrates for the first time that the absence of PCSK9 protects both wild-type and apolipoprotein E-deficient mice from atherosclerosis. This protection is dependent on the low-density lipoprotein receptor because the correlation between PCSK9 and atherosclerosis was lost in low-density lipoprotein receptor-deficient mice. Our data thus suggest that PCSK9 inhibition will be beneficial in reducing the development of atherosclerosis. In view of the selectivity of action of PCSK9 on the low-density lipoprotein receptor in the liver and possibly in the small intestine, it is expected that drugs that would target PCSK9 will exhibit fewer side effects than those related to statins. See p 894.
Metabolic Syndrome in Adolescence: Can It Be Predicted From Natal and Parental Profile? The Prediction of Metabolic Syndrome in Adolescence (PREMA) Study
The prevalence of metabolic syndrome in adolescence has gradually increased to approximately 10% in the United States and Western Europe. Because it is strongly associated with adult metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus, the early detection of children at high risk may have potential clinical
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Original Research Put Into Perspective for the Practicing Clinician Volume 125 Ⅲ Number 7 Ⅲ February 21, 2012 impact. After assessment of an overall urban population of 2361 white children and adolescents over a 10-year period, the present study showed that birth measurements and family history can be helpful for the practicing clinician in classifying children according to risk of metabolic syndrome in adolescence. The coexistence of low birth weight (Ͻ10th percentile) and small birth head circumference (Ͻ10th percentile) together with parental (in at least 1 parent) overweight or obesity was found to predict metabolic syndrome in adolescence with a sensitivity of 91% and a specificity of 98%. Thus, the coexistence of low birth weight, small head circumference, and parental history of overweight or obesity may be helpful in targeting children at risk for developing metabolic syndrome in adolescence who may benefit especially from early institution of heart-healthy behaviors. See p 902.
Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia
Preeclampsia is one of the most common medical complications of pregnancy, yet identification of patients at risk for preeclampsiarelated adverse outcome remains elusive. Circulating angiogenic factors are involved in the pathogenesis of preeclampsia; thus, we hypothesized that altered angiogenic factor levels predict adverse maternal and perinatal outcomes in women being evaluated for preeclampsia. Here, we report 3 new findings. First, in women with suspicion of preeclampsia, the ratio of soluble fms-like tyrosine kinase 1 (sFlt1) to placental growth factor (PlGF) at presentation is strongly associated with subsequent maternal and perinatal adverse outcomes. Second, in women presenting at Ͻ34 weeks' gestation, the sFlt1/PlGF ratio performs better than other currently available clinical signs and laboratory tests in the prediction of adverse outcomes. Third, the sFlt1/PlGF ratio is inversely correlated with the duration of pregnancy. Estimating the timing of delivery will help risk stratify patients, determine whether patients should be transferred to a tertiary care facility for anticipated delivery, and assess whether administration of steroids is warranted. The sFlt1/PlGF ratio accurately predicts subsequent adverse outcomes and has the potential to decrease costs associated with multiple outpatient evaluations and inpatient admissions in women with suspected preeclampsia. See p 911.
Gremlin Plays a Key Role in the Pathogenesis of Pulmonary Hypertension
Pulmonary hypertension is a disease characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance. It occurs commonly in chronic hypoxic lung diseases and leads to increased morbidity and mortality. A major breakthrough in our understanding of pulmonary hypertension was achieved with the identification of heterozygous mutations in the bone morphogenetic receptor type 2 as the cause of the rare heritable form of pulmonary arterial hypertension. It was subsequently found that bone morphogenetic protein signaling was reduced in many other common forms of pulmonary hypertension, including hypoxic pulmonary hypertension. However, the mechanism underlying this reduction has not been clearly elucidated. Here, we report that gremlin, a secreted extracellular antagonist of bone morphogenetic proteins, was expressed more highly in pulmonary endothelial cells in vitro than in the endothelium of other organs and was markedly increased in response to hypoxia. We show that gremlin was increased selectively in the hypoxic mouse lung and that genetically manipulated mice with reduced gremlin expression showed attenuation of hypoxic pulmonary vascular remodeling and reduced pulmonary vascular resistance. Furthermore, we found that gremlin was increased in the small intrapulmonary vessels of lungs explanted from patients with pulmonary arterial hypertension. Thus, we have identified a novel mechanism contributing to the development of pulmonary hypertension, which, because it is an extracellular protein, represents an attractive potential therapeutic target. See p 920.
